



Study of Drug Interactions in Cancer Therapy and Their Management in Cancer Patients at the Outpatient Polyclinic of General Hospital "X" in 2020

Anak Agung Ngurah Putra Riana Prasetya^{1*}, Mahadri Dhrik², Pande Made Desy Ratnasari¹, Ni Luh Sri Adi Suryani¹

¹ Bachelor of Pharmacy Study Program, Sekolah Tinggi Farmasi Mahaganesha, Denpasar, Bali, Indonesia

² Diploma of Pharmacy Study Program, Sekolah Tinggi Farmasi Mahaganesha, Denpasar, Bali, Indonesia

ABSTRACT: Chemotherapy is commonly used in cancer patients either as a monotherapy or in combination, as it demonstrates higher effectiveness and lower toxicity compared to single-agent use, while also preventing drug resistance. The combination of chemotherapy drugs, or their use alongside supportive drugs, can increase the risk of drug interactions that may affect treatment outcomes. The purpose of this research is to examine and offer suggestions for the management of medication interactions in cancer patients at the X Cancer Centre polyclinic of X Denpasar Hospital in 2020. The present investigation is a cross-sectional descriptive study with retrospective data collection from medical records in 2020. Drug interaction data were analyzed using Drugs.com, Lexicomp, and Stockley to assess the type of interaction, risk level, severity, and management of each interaction. The results indicated that the most common types of cancer were breast cancer (62.7%) and lymphoma (10.2%), with combination chemotherapy being used in 73.97% of cases. The most frequent type of interaction was pharmacodynamic interaction (50.42%), with risk level C (35.53%) and moderate severity (69.07%). The most common interactions were between chemotherapy drugs and supportive drugs (46.47%). The recommended management of potential drug interactions in cancer patients includes providing a time gap between drug administrations.

Keywords: Drug interactions; cancer; chemotherapy

*Corresponding author:

Name : Anak Agung Ngurah Putra Riana Prasetya

Email : gungtra.apoteker95@gmail.com

Address : Sekolah Tinggi Farmasi Mahaganesha, Denpasar, Bali, Indonesia

INTRODUCTION

Cancer is a condition involving the abnormal growth of body cells that can develop and spread to other parts of the body, disrupting organ growth and potentially leading to death (Yeoh et al., 2015). Cancer patients in the world are estimated to reach 19.3 million cases, with 10 million deaths, and as many as 68 thousand cases of breast cancer are found in Indonesia, with 22 thousand deaths. Common cancer cases in Indonesia are lung cancer, breast cancer, prostate cancer, colorectal cancer, stomach cancer, and liver cancer (Firdaus & Susilowati, 2023; Sung et al., 2021). The growth and development of cancer cells are influenced by the disruptions in deoxyribonucleic acid (DNA) formation, which triggers abnormalities in gene division (gene mutation). Several factors contribute to cancer cell growth, including exposure to carcinogenic substances, oncogenic viruses, environmental factors, economic factors, diet, and alcohol consumption (Alipour, 2021; Sun et al., 2020).

Chemotherapy is one of the commonly used methods as an anticancer agent, used singly or in combination, with a mechanism of action that suppresses proliferation, spread and destroys cancer cells (cytotoxic). The cytotoxic effect of chemotherapy drugs destroys cancer cells and affects normal cells, which can lead to harmful side effects (Firdaus & Susilowati, 2023). Combinations of chemotherapy drugs are commonly used because they are more effective and have lower toxicity compared to single-agent use, and they can prevent or slow drug resistance (Rusdi et al., 2023). Another widely used treatment approach is the combination of chemotherapy drugs with supportive drugs, which are used as premedication before chemotherapy and as post-chemotherapy therapy.

The use of drug combinations can cause drug-related problems (DRP). Drug-related problems (DRP) are unexpected events caused by treatment that can potentially affect and disrupt the success of therapy. One of the issues within DRPs is drug interactions, which can affect clinical outcomes during treatment (Mantang et al., 2023). Drug interactions are categorised into three types, namely pharmaceutical interactions, pharmacokinetic interactions, and pharmacodynamic interactions. Drug interactions may occur due to excessive drug use in a single prescription, known as polypharmacy. Another study reported that the incidence of DRP due to ineffective medication was 26.67%, and due to drug interactions was 66.67% (Nayak et al., 2021).

Based on this, several studies on drug interactions in cancer patients have been conducted. One study found that the potential for drug interactions in cancer patients at X West Java hospital from 2019 to 2021 involved 428 cases, with 88.17% having moderate significance (Rusdi et al., 2023). Another study mentioned that prescribing more than seven types of drugs, or three or more types of cancer drugs, carries a high risk of drug interactions (Ismail et al., 2020). Another study examining drug interactions in cancer patients found that 50.1% of drug interactions were caused by pharmacodynamic mechanisms, 27% by pharmacokinetic mechanisms, and 23.6% had an unknown interaction mechanism (Ramasubbu et al., 2021).

Based on these studies, the high potential for drug interactions during treatment can affect treatment outcomes and increase the risk of side effects. Drug interactions can be mitigated by assessing the interactions of the drugs given to cancer patients (Faizah, 2018). Thus, the purpose of this study was to evaluate the possibility of drug interactions and offer suggestions for handling drug interaction incidents in cancer patients at the X General Hospital Denpasar's X Cancer Centre outpatient clinic over the course of 2020.

METHODS

Research Design

This study used an observational cross-sectional design and employed descriptive methods with retrospective data collection from the outpatient polyclinic at X Cancer Center, X Denpasar General Hospital. The study population and sample included all medical records and pharmacy data of patients diagnosed with cancer who underwent chemotherapy in 2020.

Sampling Technique

The sampling technique in this study uses purposive sampling with specific considerations in sampling. The inclusion criteria in the study were cancer patients undergoing outpatient chemotherapy who had complete drug data (chemotherapy regimen, premedication drugs, and post-chemotherapy). The exclusion criteria were patients undergoing chemotherapy whose medical records had unclear or unreadable drug names, and cancer patients undergoing chemotherapy did not receive premedication therapy or post-chemotherapy drugs. Based on the inclusion and exclusion criteria, a total of 118 samples were obtained.

Research Instruments

The research instrument used was a data collection table containing the patient's name initials, medical record number, gender, chemotherapy drugs used, premedication drugs, and post-chemotherapy drugs, which would later be placed in the drug interaction assessment analysis table. The data obtained was stored using the Microsoft Excel application. The type of data used was quantitative data, which included patient population data, chemotherapy drugs used, and drugs used before and after undergoing chemotherapy.

Data Analysis

Demographic and drug interaction data were analyzed descriptively using a percentage table. Analysis of patient demographics included data on gender, age, occupation, and type of cancer experienced by the patient, while the drug interactions analysis was determined based on the significance standards found on the official website of Lexicomp (2023), Drugs.com (2023), and Stocktey's Drug Interactions (2015). Drug interaction analysis was conducted by comparing interactions that occurred in patients with those recorded in the literature. The percentage of drug interactions was determined based on the types of drug interactions that occurred, the level of risk factors set by the Food and Drug Administration (FDA), and the significance of interactions from several risk factors reviewed based on the severity caused by drug interactions (severity). The following equation was used in calculating the percentage of drug interaction events and the significance of interactions is as follows:

$$\% \text{Potential drug interactions} = \frac{\text{Number of drug interaction types}}{\text{Total of drug interactions}} \times 100\%$$

%Potential drug interactions based on significance=

$$\frac{\text{Number of interactions by significance category}}{\text{Total of drug interactions by significance category}} \times 100\%$$

Analysis of drug interactions based on the level of risk is grouped into several categories: category A indicates that there is no evidence of drug interactions, category B indicates evidence of potential drug interactions with little clinical effect, category C

indicates clinical significance so that monitoring is required, Category D indicates the need for changes (dose, alternative therapy, or monitoring) and Category X indicates that avoiding it is advisable due to its high risk. Meanwhile, severity-based analysis classified interactions as major (potentially causing death or permanent disability), moderate (resulting in clinical status changes), or minor (with negligible effects that do not require additional therapy) (Shetty et al., 2018; Yuliawati et al., 2021). This study also included management recommendations for each identified drug interaction as supporting data.

RESULT AND DISCUSSION

Characteristics Sample

A total of 118 samples met the inclusion criteria of cancer patients undergoing outpatient chemotherapy at the X Cancer Center Polyclinic, X Denpasar General Hospital, in 2020. Table 1 shows that the highest average age of cancer patients falls within the 44 to 53 year range (32%), with a higher proportion of female patients (82%) compared to male patients (18%). Females are at greater risk of developing cancer due to hormonal influences, such as estrogen, which plays a role in regulating menstruation and the menopausal process. Prolonged exposure to this hormone can increase cancer risk (Hasnita & Arif Harahap, 2019; Wardana & Ernawati, 2019). Twelve types of cancer were identified among the patients, with the most common being breast cancer (62.7%), non-Hodgkin lymphoma (10.2%), rectal cancer (7.6%), and colorectal cancer (5.9%). Previous studies have shown that most breast cancer cases occur between the ages of 45 and 64, due to the increased cancer risk associated with aging and accumulated genetic damage (Elmika & Adi, 2020; Sari & Gumayesty, 2016).

Drug Utilization Profile

Chemotherapy drugs are cytostatic agents used to inhibit the proliferation of cancer cells and induce cell destruction. These drugs, whether used as monotherapy or in combination, are commonly administered to cancer patients (Firdaus & Susilowati, 2023). At X General Hospital, chemotherapy regimens include both monotherapy and combination therapy. This study found that 26.03% of patients received chemotherapy as monotherapy, while 73.97% were treated with combinations of two or more chemotherapy drugs.

Based on the data in Table 2, the most frequently used combination of two chemotherapy drugs was carboplatin and paclitaxel, accounting for 7.32%. This combination is commonly used in patients with triple-negative breast cancer (TNBC), an aggressive form of breast cancer that does not respond to standard therapies. TNBC lacks the expression of several receptors, such as progesterone and estrogen receptors, but often involves overexpression of the Human Epidermal Growth Factor Receptor 2 (HER-2), a receptor that regulates cell growth and repair in breast tissue (Amitria et al., 2018; Permana et al., 2019; Yu et al., 2020).

This study also identified combinations involving three chemotherapy drugs, with the most common being 5-Fluorouracil, Doxorubicin, and Cyclophosphamide, used in 13.82% of cases. This regimen significantly reduces the risk of breast cancer recurrence by interfering with DNA replication during the cancer cell development cycle. It is typically administered intravenously every three weeks for six cycles (Irawati & Sardjan, 2022; Pereira-Oliveira et al., 2019). The use of combination chemotherapy aims to improve

tolerability and effectiveness while reducing drug resistance in cancer patients (Wu et al., 2020).

Table 1. Patients Demographics

| Patient Demographics | | Total | % |
|-----------------------------|------------------------|--------------|------------|
| age | 24 – 33 | 6 | 5 |
| | 34 – 43 | 25 | 21 |
| | 44 – 53 | 38 | 32 |
| | 54 - 63 | 34 | 29 |
| | 64 - 73 | 15 | 13 |
| | Total | 118 | 100 |
| Sex | Female | 97 | 82 |
| | Male | 21 | 18 |
| | Total | 118 | 100 |
| Type Cancer | Breast Cancer | 74 | 62.7 |
| | Non-Hodgkin's Lymphoma | 12 | 10.2 |
| | Rectal Cancer | 9 | 7.6 |
| | Colon Cancer | 7 | 5.9 |
| | Cervical Cancer | 4 | 3.4 |
| | Ovarian Cancer | 3 | 2.5 |
| | Plasma Cell Cancer | 3 | 2.5 |
| | Nasopharyngeal Cancer | 2 | 1.7 |
| | Blood Cancer | 1 | 0.8 |
| | Esophageal Cancer | 1 | 0.8 |
| | Lung Cancer | 1 | 0.8 |
| | Prostata Cancer | 1 | 0.8 |
| | Total | 118 | 100 |

Table 2. Chemotherapy Drugs Used

| Drug | Total | % |
|--------------------------------|--------------|---------------|
| Monotherapy | | |
| Trastuzumab | 7 | 5.69% |
| Gemcitabine | 5 | 4.09% |
| Paclitaxel | 4 | 3.25% |
| Capecitabine | 4 | 3.25% |
| Bevacizumab | 3 | 2.44% |
| Other | 9 | 7.31% |
| Total | | 26.03% |
| 2 Combination Therapy | | |
| Carboplatin + Paclitaxel | 9 | 7.32% |
| Doxorubicin + Paclitaxel | 9 | 7.32% |
| Capecitabine + Oxaliplatin | 8 | 6.50% |
| Cyclophosphamide + Doxorubicin | 5 | 4.07% |
| Paclitaxel + Trastuzumab | 3 | 2.44% |
| Pertuzumab + Trastuzumab | 3 | 2.44% |
| Other | 15 | 12.19% |

| Drug | Total | % |
|---|-------|---------------|
| 3 Combination Therapy | | |
| 5-Fluorouracil + Doxorubicin + Cyclophosphamide | 17 | 13.82% |
| Doxorubicin + Cyclophosphamide + Vincristine | 11 | 8.94% |
| 5-Fluorouracil + Irinotecan + Leucovorin | 3 | 2.44% |
| Doxorubicin + Paclitaxel + Trastuzumab | 2 | 1.63% |
| Other | 5 | 4.05% |
| 4 Combination Therapy | | |
| 5-Fluorouracil + Bevacizumab + Leucovorin + Oxaliplatin | 1 | 0.81% |
| Total | | 73.97% |
| Total Monotherapy + Combination Therapy | | 100% |

In addition to chemotherapy drugs, cancer patients commonly use supportive medications (Table 3) to reduce or manage the side effects caused by chemotherapy. These supportive therapies include drugs administered before (premedication) and after (post-medication) chemotherapy. The most frequently used supportive drugs were antihistamines (31.61%), corticosteroids (31.31%), and 5-HT3 receptor antagonists (21.88%). First-generation antihistamines are commonly used in cancer patients undergoing chemotherapy to manage hypersensitivity reactions and side effects associated with chemotherapy drugs (Fritz et al., 2021). Other studies have also reported that the use of antihistamines (e.g., diphenhydramine), corticosteroids (e.g., dexamethasone), and 5-HT3 receptor antagonists (e.g., ondansetron) effectively reduces and controls chemotherapy-induced nausea and vomiting (Shinta R & Surarso, 2016).

Table 3. The usage of other drugs

| Drug | Total | % |
|-----------------------------|------------|-------------|
| Antihistamine | 104 | 31,61% |
| Corticosteroids | 103 | 31,31% |
| 5-HT3 Receptor Antagonists | 72 | 21,88% |
| Supplement | 26 | 7,90% |
| Proton Pump Inhibitor (PPI) | 9 | 2,74% |
| Analgesics | 6 | 1,82% |
| Anticoagulan | 1 | 0,30% |
| H2 Antagonist | 1 | 0,30% |
| Other | 7 | 2,13% |
| Total | 329 | 100% |

Drug Interaction Assessment

The use of chemotherapy drugs in combination with supportive therapy in cancer patients carries a high risk of drug interactions. This potential arises from the concurrent use of multiple medications, often due to comorbidities and the advanced age of patients (Rabba et al., 2020; Riechelmann & Krzyzanowska, 2019). Studying drug interactions is essential for estimating potential risks and planning appropriate management strategies to reduce or prevent adverse interactions (Hammad et al., 2017).

This study reviewed drug interactions in cancer patients undergoing chemotherapy using both free and paid resources, such as Drugs.com, Lexicomp, and Stockley's Drug Interactions. The results indicated that the most common type of interaction was

pharmacodynamic (50.42%). Similar findings were reported in another study, where pharmacodynamic interactions accounted for 50.1%, surpassing pharmacokinetic (26.6%) and unknown (23.3%) interactions (Ramasubbu et al., 2021). One example of a pharmacodynamic interaction identified in this study was between doxorubicin and 5-fluorouracil, which can lead to myelosuppression and gastrointestinal bleeding (Nayak et al., 2021).

Pharmacodynamic interactions occur when two drugs share similar or opposing pharmacological targets, therapeutic effects, or side effects. These interactions typically involve active compounds that mutually alter pharmacological effects, either reinforcing, adding to, or antagonizing each other, leading to unwanted reactions (Ramdani et al., 2022). Another type of potential interaction observed was pharmacokinetic, accounting for 27.97%. An example of this interaction is between doxorubicin and dexamethasone, where dexamethasone may decrease the blood levels of doxorubicin (Drug.com, 2023). Pharmacokinetic interactions occur when one drug affects the absorption, distribution, metabolism, or excretion of another drug, altering plasma concentrations. This effect can result from the inhibition or induction of cytochrome P450 (CYP) enzymes in the body (Rizo et al., 2020).

The assessment of drug interactions based on risk level is categorized into five groups: A, B, C, D, and X. As shown in Table 4, the most common risk levels were C (35.53%) and D (34.21%). Based on severity, drug interactions can be classified as major, moderate, or minor. Major interactions have significant clinical consequences, moderate interactions can alter the patient's clinical status, and minor interactions cause mild disturbances that do not substantially affect therapeutic outcomes (Feinstein et al., 2015). The most frequent interaction severity in this study was moderate (69.07%).

Table 4. Potential Interaction Characteristics

| Characteristic | % |
|-------------------|-------------|
| Type Interactions | |
| Pharmacodynamic | 50.42% |
| Pharmacokinetic | 27.97% |
| Unknown | 21.61% |
| Total | 100% |
| Risk Level | |
| C | 35.53% |
| D | 34.21% |
| B | 30.26% |
| Total | 100% |
| Severity | |
| Moderate | 69.07% |
| Major | 19.49% |
| Minor | 11.44% |
| Total | 100% |

Table 5 shows that the potential for drug interactions is higher in the combination of chemotherapy drugs and supportive drugs (46.47%) than in the interaction between chemotherapy drugs alone (41.08%) or between supportive drugs alone (12.45%). Similar findings have been reported in other studies, which also indicated that the potential for drug interactions was higher when chemotherapy drugs were combined with supportive drugs (Laban et al., 2021). The combination of dexamethasone and paclitaxel (25%) was the most frequently observed drug interaction in cancer patients, followed by the

combination of cyclophosphamide and ondansetron (18.75%), and the interaction between doxorubicin and dexamethasone (11.61%). The interaction between dexamethasone and paclitaxel is a pharmacokinetic interaction with moderate severity. Dexamethasone is an inducer of the cytochrome P450 enzyme CYP3A4, which can lower paclitaxel levels in the blood, thus reducing its effectiveness. Management strategies include monitoring the therapeutic response to paclitaxel, administering dexamethasone 30 minutes prior to paclitaxel infusion, and using dexamethasone as premedication to reduce the risk of hypersensitivity reactions caused by paclitaxel (D'Errico et al., 2020).

We classify the interaction between cyclophosphamide and ondansetron as an unknown interaction of minor severity, with a risk level of B. Ondansetron may reduce the pharmacological effects and alter the systemic exposure of cyclophosphamide. Both drugs are metabolised in the liver, with ondansetron having an onset time of 30 minutes and cyclophosphamide having a half-life of 3–12 hours, excreted through urine. Management strategies for this combination include allowing a 1–2 hour gap between administrations or considering safer antiemetic options, such as palonosetron (Drug.com, 2023; Koni et al., 2022; Ramasubbu et al., 2021).

The potential interaction between oxaliplatin and ondansetron is classified as moderate in severity, with a pharmacodynamic interaction type that has an additive effect, increasing the risk of irregular heart rhythms, which could potentially lead to death (Drug.com, 2023; Williamson & Polwart, 2016). Management strategies include closely monitoring the QT interval via electrocardiogram (ECG). Patients should be advised to seek immediate medical attention if they experience dizziness or irregular heartbeats. To minimize the risk of interaction, the ondansetron dose can be adjusted to 8 mg, or alternatives such as granisetron or palonosetron, other drugs in the 5-HT3 receptor antagonist class, can be considered (de Lemos et al., 2019; Drug.com, 2023).

Based on Table 5, 41.08% of potential drug interactions were observed in combinations of chemotherapy drugs. The most common interaction was between paclitaxel and trastuzumab (15.78%), which involves an unknown interaction type with moderate severity. This combination is frequently used as a first-line treatment in patients with metastatic breast cancer. It may increase the serum concentration of trastuzumab while decreasing the serum concentration of paclitaxel, which can increase the risk of cardiotoxicity with long-term use of trastuzumab (Büyükköroğlu et al., 2016). Management strategies for this interaction include periodic monitoring of the patient's heart function via ECG. Patients should also be advised to consult their doctor immediately if they experience symptoms such as chest pain, nausea, sweating, coughing, or wheezing (Drug.com, 2023).

Another significant interaction was observed between doxorubicin and cyclophosphamide, which is classified as a pharmacokinetic interaction with major severity and risk level C. This interaction increases the risk of doxorubicin-induced cardiotoxicity, which can lead to permanent heart damage or even death (Jamali et al., 2021; Kurniawati et al., 2021). To manage this interaction, it is recommended to monitor heart function before and during treatment, consider using a lower dose of cyclophosphamide compared to doxorubicin, administer cyclophosphamide via infusion, and use liposomal doxorubicin to reduce toxic effects (Atalay et al., 2014; Drug.com, 2023).

Table 5. Category of Potential Drug Interactions

| NO | Drug | Other Drug | Potentially Interaction | | | Total | % |
|--|------------------|------------------|-------------------------|------------|------------------|-------|--------|
| | | | Severity Level | Risk Level | Type Interaction | | |
| Potential Chemotherapy Drug Interactions with Ancillary Drugs (46.47%) | | | | | | | |
| 1 | Dexamethasone | Paclitaxel | Moderat* | - | PK | 28 | 25% |
| 2 | Cyclophosphamide | Ondansetron | Minor** | B | Unknown | 21 | 18.75% |
| 3 | Doxorubicin | Dexamethasone | Moderat* | - | PK | 13 | 11.61% |
| 4 | Dexamethasone | Vincristine | Moderat* | - | PK | 12 | 10.71% |
| 5 | Oxaliplatin | Ondansetron | Moderat* | - | PD | 10 | 8.93% |
| 6 | Doxorubicin | Ondansetron | Moderat* | - | PD | 8 | 7.14% |
| 7 | Carboplatin | Pantoprazole | Moderat* | - | PD | 7 | 6.25% |
| 8 | Doxorubicin | Palonosetron | Moderat* | - | PD | 6 | 5.36% |
| 9 | Dexamethasone | Irinotecan | Moderat* | - | PK | 3 | 2.68% |
| 10 | Dexamethasone | Bortezomib | Minor ** | B | PK | 2 | 1.79% |
| 11 | Dexamethasone | Vinorelbine | Moderat* | - | PK | 1 | 0.89% |
| 12 | Capecitabine | Omeprazole | Moderat** | C | Unknown | 1 | 0.89% |
| Total | | | | | | | 100% |
| Potential Interactions Between Chemotherapy Drugs (41.08%) | | | | | | | |
| 1 | Paclitaxel | Trastuzumab | Moderat* | - | Unknow | 15 | 15.78% |
| 2 | Cyclophosphamide | Doxorubicin | Mayor** | C | PK | 13 | 13.68% |
| 3 | Doxorubicin | 5-Fluorouracil | Moderat* | - | PD | 13 | 13.68% |
| 4 | Cyclophosphamide | 5-Fluorouracil | Moderat* | - | PD | 13 | 13.68% |
| 5 | Doxorubicin | Paclitaxel | Mayor** | D | PK | 11 | 11.57% |
| 6 | Carboplatin | Paclitaxel | Mayor** | D | Unknown | 9 | 9.47% |
| 7 | Oxaliplatin | Capecitabine | Moderat* | - | PD | 6 | 6.31% |
| 8 | Leucovorin | 5-Fluorouracil | Mayor* | - | PD | 5 | 5.26% |
| 9 | Doxorubicin | Trastuzumab | Mayor* | - | Unknown | 3 | 3.15% |
| 10 | Carboplatin | Gemcitabine | Moderat* | - | Unknown | 2 | 2.10% |
| 11 | Oxaliplatin | 5-Fluorouracil | Moderat* | - | PD | 2 | 2.10% |
| 12 | Tamoxifen | Goserelin | Moderat* | - | PK | 2 | 2.10% |
| 13 | Doxorubicin | Carboplatin | Moderat** | D | PD | 1 | 1.05% |
| Total | | | | | | | 100% |
| Potential Interactions Between Ancillary Drugs (12.45%) | | | | | | | |
| 1 | Ondansetron | Palonosetron | Moderat* | - | PD | 10 | 33.33% |
| 2 | Dexamethasone | Alprazolam | Minor* | - | PD | 4 | 13.13% |
| 3 | Dexamethasone | Celecoxib | Moderat* | - | PD | 3 | 10.10% |
| 4 | Dexamethasone | Oxycodon | Mayor* | - | PD | 2 | 6.67% |
| 5 | Diphenhydramine | Oxycodon | Mayor** | D | PD | 2 | 6.67% |
| 6 | Ondansetron | Oxycodon | Moderat* | - | PD | 1 | 3.33% |
| 7 | Dexamethasone | Rivaroxaban | Moderat* | - | PK | 1 | 3.33% |
| 8 | Dexamethasone | Meloxicam | Moderat** | C | PD | 1 | 3.33% |
| 9 | Diphenhydramine | Alprazolam | Moderat** | C | PD | 1 | 3.33% |
| 10 | Diphenhydramine | Metoclorpramide | Moderat** | C | PD | 1 | 3.33% |
| 11 | Diphenhydramine | Atropine sulfate | Moderat** | C | PD | 1 | 3.33% |
| 12 | Diphenhydramine | Amitriptyline | Moderat** | C | PD | 1 | 3.33% |
| 13 | Amitriptyline | Morfine | Mayor** | D | PD | 1 | 3.33% |
| 14 | Cimetidine | Alprazolam | Moderat** | C | PK | 1 | 3.33% |
| Total | | | | | | | 100% |

*drug.com; **Lexicomp; PK= Pharmacokinetics; PD= Pharmacodynamics (Drug.com. 2023; Lexicom. 2023)

A potential interaction was also found between supporting drugs, specifically ondansetron and palonosetron, which accounted for 33.33% of interactions in this category. This interaction is classified as pharmacodynamic with moderate severity. The

combined use of these drugs can increase the risk of QT prolongation, which may lead to arrhythmias and death (Novita & Destiani, 2019). Management strategies include monitoring heart rhythm using ECG and ensuring that there is a time interval between the administration of ondansetron and palonosetron. If possible, palonosetron alone should be used, as it is a second-generation 5-HT3 receptor antagonist with stronger receptor affinity, a longer elimination half-life (approximately 40 hours), and is more effective in controlling nausea and vomiting during chemotherapy (Drug.com, 2023; Umar, 2018).

Table 6. Drug Interaction Management

| No | Drug | Other Drug | Interactions based on literature | Restriction Management based on literature |
|---|------------------|---------------|--|---|
| Potential Chemotherapy Drug Interactions with Ancillary Drugs (46,47%) | | | | |
| 1 | Dexamethasone | Paclitaxel | Co-administration with drugs that induce CYP450 2C8 and/or 3A4 (dexamethasone) may reduce plasma concentrations or blood levels of Paclitaxel*. | <ul style="list-style-type: none"> Monitoring for decreased therapeutic response to paclitaxel* Dexamethasone administered no later than 30 minutes before paclitaxel |
| 2 | Cyclophosphamide | Ondansetron | Ondansetron may decrease the serum concentration of Cyclophosphamide**. | <ul style="list-style-type: none"> No intervention required* |
| 3 | Doxorubicin | Dexamethasone | Co-administration with drugs that induce CYP450 2C8 and/or 3A4 (dexamethasone) may reduce plasma concentrations or blood levels of Doxorubicin*. | <ul style="list-style-type: none"> Monitoring for decreased therapeutic response to Doxorubicin* Dexamethasone administered no later than 1-2 hours before Doxorubicin |
| 4 | Dexamethasone | Vincristine | Decreases the effect of plasma concentrations of Vincristine* | <ul style="list-style-type: none"> Dexamethasone is administered 1-2 hours before vincristine* |
| 5 | Oxaliplatin | Ondansetron | Increased risk of QT prolongation* | <ul style="list-style-type: none"> Regular monitoring of cardiac function and rhythm by performing an electrocardiogram* Dose adjustment is required, and alternatives such as Granisetron or palonosetron may be substituted if possible |
| 6 | Doxorubicin | Ondansetron | Increased risk of QT prolongation* | <ul style="list-style-type: none"> Regular monitoring of heart function and rhythm* |
| 7 | Carboplatin | Pantoprazole | Use of proton pump inhibitors (pantoprazole) may increase hypomagnesia* | <ul style="list-style-type: none"> Clinical and laboratory monitoring of hematologic and non-hematologic toxicity is required* Substitution with histamine type-2 receptor antagonists or the addition of sucralfate is recommended if hypomagnesia is indicated. |
| 8 | Doxorubicin | Palonosetron | Increased risk of QT prolongation* | <ul style="list-style-type: none"> Regular monitoring of heart function and rhythm* |

| No | Drug | Other Drug | Interactions based on literature | Restriction Management based on literature |
|---|------------------|----------------|---|--|
| 9 | Dexamethasone | Irinotecan | Reduced therapeutic effect and blood levels of irinotecan* | <ul style="list-style-type: none"> Monitoring the pharmacological response of irinotecan* Dexamethasone is given 30 minutes before irinotecan No intervention required* |
| 10 | Dexamethasone | Bortezomib | Decreases serum concentration of bortezomib** | <ul style="list-style-type: none"> Special care is needed if we use the medicine together* |
| 11 | Dexamethasone | Vinorelbine | Reduces the effects and blood levels of vinorelbine* | <p>A change of medication is recommended if possible*</p> <ul style="list-style-type: none"> Special monitoring of reduced efficacy of capecitabine is required** Consideration of the use of simethicone |
| 12 | Capecitabine | Omeprazole | Use of proton pump inhibitors (omeprazole) may reduce the therapeutic effect of capecitabine** | |
| Potential Interactions Between Chemotherapy Drugs (41,08%) | | | | |
| 1 | Paclitaxel | Trastuzumab | Paclitaxel may enhance the cardiotoxic effects of trastuzumab | <ul style="list-style-type: none"> Regular monitoring of the patient's heart function by conducting an electrocardiogram* Recommended that if the patient experiences symptoms of chest pain, immediately consult a doctor.* Monitor heart function** Suggested a lower dose of cyclophosphamide than doxorubicin** Suggested use of liposomal doxorubicin to reduce cardiotoxic risk** |
| 2 | Cyclophosphamide | Doxorubicin | Cyclophosphamide increases the cardiotoxic effects of doxorubicin | |
| 3 | Doxorubicin | 5-Fluorouracil | Concurrent or sequential administration may cause additive toxicity, especially in the bone marrow and gastrointestinal tract.* | <ul style="list-style-type: none"> Clinical monitoring as well as laboratory examination of haematologic and non-haematologic toxicity and dose adjustment of each drug* |
| 4 | Cyclophosphamide | 5-Fluorouracil | Increased risk of side effects, especially those affecting the bone marrow and gastrointestinal tract* | <ul style="list-style-type: none"> Monitoring side effects with clinical and laboratory monitoring for hematologic and non-hematologic toxicity* Dose adjustment is required if the patient develops fever, chills, and diarrhea during treatment.* |
| 5 | Doxorubicin | Paclitaxel | Paclitaxel may increase doxorubicin-induced cardiovascular toxicity.** | <ul style="list-style-type: none"> Monitoring of heart function** Doxorubicin is given first, at least 24 hours before paclitaxel, and it is recommended to add the cytoprotective drug dexrazoxane. |

| No | Drug | Other Drug | Interactions based on literature | Restriction Management based on literature |
|----|-------------|----------------|---|---|
| 6 | Carboplatin | Paclitaxel | Increased risk of myelosuppressive side effects from Paclitaxel ** | <ul style="list-style-type: none"> Paclitaxel infusion is given first before carboplatin; this order of administration reduces platelet toxicity** If the patient develops peripheral neuropathy, this combination should be stopped immediately to reduce further damage |
| 7 | Oxaliplatin | Capecitabine | Causes additive toxicity, especially in the bone marrow and gastrointestinal tract* | If co-administered, more frequent monitoring of doses tailored to the patient's needs is required* |
| 8 | Leucovorin | 5-Fluorouracil | The combination of these drugs has a synergistic effect, potentially causing cardiotoxicity, cardiomyopathy, heart failure, diarrhoea, mucositis, and myelosuppression. | <ul style="list-style-type: none"> Special monitoring of the dose, it is recommended that the dose of 5-FU is smaller than leucovorin, and the potential toxicity of 5-FU, such as thrombocytopenia, neutropenia, can be monitored by conducting laboratory tests * The use of this drug combination should not be used or continued if the patient has symptoms of gastrointestinal toxicity until the symptoms disappear* |
| 9 | Doxorubicin | Trastuzumab | Trastuzumab induced doxorubicin, resulting in increased cardiotoxic effects such as cardiomyopathy* | <ul style="list-style-type: none"> Monitoring of blood drug levels and heart function* If possible, the use of anthracycline therapy should be avoided for up to 7 months after discontinuation of trastuzumab* |
| 10 | Carboplatin | Gemcitabine | Increased risk of side effects, neurotoxicity, nephrotoxicity, and ototoxicity* | <ul style="list-style-type: none"> Use of Carboplatin infusion after gemcitabine* During the administration of this combination, do not use simultaneously with NSAID drugs |
| 11 | Oxaliplatin | 5-Fluorouracil | Increased neutropenia and anemia incidence, peripheral neuropathy, and hypersensitivity reactions | <ul style="list-style-type: none"> Clinical and laboratory monitoring of hematologic and non-hematologic toxicities* Calcium channel blocker (CCB) drugs such as amlodipine are recommended to reduce the risk of oxaliplatin-induced peripheral neuropathy |
| 12 | Tamoxifen | Goserelin | Increased risk of irregular heart rhythms with potential death, and electrolyte disturbances* | Recommended patients have their electrolytes and heart function checked by performing an ECG* |

| No | Drug | Other Drug | Interactions based on literature | Restriction Management based on literature |
|--|-----------------|--------------|---|--|
| 13 | Doxorubicin | Carboplatin | Increases the risk of additive toxicity effects, especially in the bone marrow and gastrointestinal tract** | <ul style="list-style-type: none"> • Clinical monitoring and laboratory examination of hematological, non-hematological toxicity, and dose adjustment of each drug ** • Monitoring of side effects such as nausea and vomiting ** |
| Potential Interactions Between Ancillary Drugs (12,45%) | | | | |
| 1 | Ondansetron | Palonosetron | Increased cardiac rhythm* | <ul style="list-style-type: none"> • Closely monitoring the patient's heart rhythm by performing an ECG * • Given a time lag in its use, for example, palonosetron is given as premedication while ondansetron is given as post-chemotherapy, or if possible, use palonosetron alone |
| 2 | Dexamethasone | Alprazolam | Co-administration with drugs that induce CYP450 2C8 and/or 3A4 (dexamethasone) may reduce plasma concentrations or blood levels of Alprazolam*. | Recommended to allow about 1-2 hours between dexamethasone and alprazolam* |
| 3 | Dexamethasone | Celecoxib | Increased effects of gastrointestinal ulceration and bleeding* | Monitoring risk of side effects* |
| 4 | Dexamethasone | Oxycodon | Co-administration with drugs that induce CYP450 2C8 and/or 3A4 (dexamethasone) may reduce plasma concentrations or blood levels of Oxycodon *. | <ul style="list-style-type: none"> • Monitoring pharmacologic responses* • If used concomitantly, limit the dose of the drug to the minimum or as needed to achieve the desired therapeutic effect* |
| 5 | Diphenhydramine | Oxycodon | increased depressant effects on the central nervous system** | <ul style="list-style-type: none"> • Monitoring depression of respiration, central nervous system** • If used concomitantly, dose adjustment and dose titration are required, especially at treatment initiation** |
| 6 | Ondansetron | Oxycodon | Increased risk of serotonin syndrome* | Special monitoring for serotonin syndrome symptoms during treatment* |
| 7 | Dexamethasone | Rivaroxaban | Dexamethasone may reduce blood levels of rivaroxaban* | Dose adjustment and time interval for administration are recommended* |
| 8 | Dexamethasone | Meloxicam | Increased effects of gastrointestinal ulceration and bleeding* | <ul style="list-style-type: none"> • Monitoring side effects ** • Recommended during the use of meloxicam to add drugs that can help protect the intestines and stomach** |

| No | Drug | Other Drug | Interactions based on literature | Restriction Management based on literature |
|----|-----------------|------------------|---|---|
| 9 | Diphenhydramine | Alprazolam | Increased risk to the central nervous system due to sedative effects** | <ul style="list-style-type: none"> If used together, dose adjustment and dose titration are required, especially at treatment initiation** Second-generation antihistamines that do not increase sedative effects are recommended** |
| 10 | Diphenhydramine | Metoclopramide | Increased diastolic ripple and depressant effects on the central nervous system** | Monitoring depression of respiration, central nervous system** |
| 11 | Diphenhydramine | Atropine sulfate | Increased additive toxic effect of one of the drugs** | Monitoring depression of respiration, central nervous system** |
| 12 | Diphenhydramine | Amitriptyline | Increased additive toxic effect of one of the drugs** | Monitoring depression of respiration, central nervous system** |
| 13 | Amitriptyline | Morfine | Increased risk of serotonin syndrome** | <ul style="list-style-type: none"> Monitoring for depression of respiration, central nervous system** Limit the dose and duration of both drugs, and the initiation of opioid dose reduction should be considered |
| 14 | Cimetidine | Alprazolam | Cimetidine may prolong the effects of alprazolam** | If used, consider reducing the alprazolam dose by one-third or dosing to twice daily |

*drug.com **Lexicomp (Drug.com, 2023; Lexicom, 2023)

The use of chemotherapy and supportive drugs in cancer patients presents a high potential for drug interactions. Special attention and monitoring are essential to prevent Drug-Related Problems (DRPs). Studying potential drug interactions in cancer patients can improve the quality of healthcare services, enhance therapeutic outcomes, and ultimately increase the quality of life for patients while minimizing the risk of drug interactions. This proactive approach ensures that drug efficacy is optimized and patient safety is maintained.

CONCLUSION

The results of this study indicate that chemotherapy drug combinations are more commonly used in cancer patients, alongside additional supportive therapies, such as antihistamines, corticosteroids, and 5-HT3 receptor antagonists, which are employed as premedication and post-chemotherapy treatments. The most frequently encountered drug interactions were pharmacodynamic interactions (50.42%), major severity interactions (69.07%), and risk level C interactions (35.53%) at the X Cancer Center Polyclinic of RSU X Denpasar. Recommended management strategies to address these potential drug interactions include adjusting the timing of drug administration, considering alternative drug combinations, and ensuring ongoing monitoring of drug interactions by pharmacists or other healthcare professionals.

ACKNOWLEDGMENT

The authors would like to express their deepest gratitude to the management and staff of X Cancer Center at X General Hospital Denpasar for granting access and support during the data collection process. We also extend our appreciation to the Health Research Ethics Committee of Stikes Bina Usada Bali for providing ethical clearance and valuable guidance for this research. Special thanks to all parties who contributed directly or indirectly to the completion of this study.

AUTHOR CONTRIBUTION

AANPRP: Concepts or ideas; design; definition of intellectual content; literature search; experimental studies; data analysis; manuscript preparation.
 MD: literature search; experimental studies; data analysis.
 PMDR: Manuscript editing; manuscript review.
 NSLAS: Definition of intellectual content; literature search, manuscript preparation.

ETHICS APPROVAL

Ethical approval for this study was granted by the Health Research Ethics Committee of Stikes Bina Usada Bali under ethical number 107/EA/KEPK-BUB-2024.

CONFLICT OF INTEREST

None to declare

REFERENCES

Alipour, M. (2021). Molecular Mechanism of Helicobacter pylori-Induced Gastric Cancer. *Journal of Gastrointestinal Cancer*, 52, 23–30. <https://doi.org/10.1007/s12029-020-00518-5>/Published

Amtiria, H. R., Khairun, D., & Berawi, N. (2018). Peran Human Epidermal Growth Factor Receptor-2 pada Kanker Payudara. In *J Agromedicine Unila* (Vol. 5).

Atalay, F., Gulmez, O., & Ozsancak Ugurlu, A. (2014). Cardiotoxicity following cyclophosphamide therapy: a case report. *Journal of Medical Case Reports*, 8(1). <https://doi.org/10.1186/1752-1947-8-252>

Büyükköroğlu, G., Senel, B., Gezgin, S., & Dinh, T. (2016). The simultaneous delivery of paclitaxel and Herceptin® using solid lipid nanoparticles: In vitro evaluation. *Journal of Drug Delivery Science and Technology*, 35, 98–105. <https://doi.org/10.1016/j.jddst.2016.06.010>

de Lemos, M. L., Kung, C., Kletas, V., Badry, N., & Kang, I. (2019). Approach to initiating QT-prolonging oncology drugs in the ambulatory setting. In *Journal of Oncology Pharmacy Practice* (Vol. 25, Issue 1, pp. 198–204). SAGE Publications Ltd. <https://doi.org/10.1177/1078155217748735>

D'Errico, S., Baldari, B., Arcangeli, M., Santurro, A., Frati, P., & Fineschi, V. (2020). Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit? A case report. *Medicine (United States)*, 99(43). <https://doi.org/10.1097/MD.00000000000022814>

Drug.com. (2023). Drug Interaction Checker: https://www.drugs.com/drug_interactions.html.

Elmika, E., & Adi, M. S. A. (2020). Gambaran Umur, dan Jenis Kelamin Pasien Kanker Payudara di RS Ibnu Sina Kota Makassar. *Jurnal Penelitian Kesehatan "SUARA FORIKES"* (Journal of Health Research "Forikes Voice"), 11(1), 1. <https://doi.org/10.33846/sf11101>

Faizah, A. K. (2018). Kajian Interaksi Obat Pada Pasien Pneumonia Di RS Pendidikan Surabaya. *SCIENTIA Jurnal Farmasi Dan Kesehatan*, 8(1), 86–91. <http://www.journalscientia.org/index.php/scientia>

Feinstein, J., Dai, D., Zhong, W., Freedman, J., & Feudtner, C. (2015). Potential drug-drug interactions in infant, child, and adolescent patients in Children's Hospitals. *Pediatrics*, 135(1), e99–e108. <https://doi.org/10.1542/peds.2014-2015>

Firdaus, N. Z., & Susilowati, S. (2023). Evaluasi Penggunaan Kemoterapi Pada Pasien Kanker Payudara Di Rumah Sakit Islam Sultan Agung Semarang Tahun 2022. *Jurnal Ilmu Farmasi Dan Farmasi Klinik (JIFFK)*, 20(2), 155–166. <https://dinkes.semarangkota.go.id/>

Fritz, I., Wagner, P., & Olsson, H. (2021). Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. *Translational Oncology*, 14(4). <https://doi.org/10.1016/j.tranon.2021.101029>

Hammad, M. A., Tangiisuran, B., Kharshid, A. M., Abdul-Aziz, N., Hassan, Y., Aziz, N. A., & Elsayed, T. M. (2017). Drug-drug interaction-related uncontrolled glycemia. *Journal of Pharmacy and Bioallied Sciences*, 9(4), 221–228. https://doi.org/10.4103/JPBS.JPBS_26_17

Hasnita, Y., & Arif Harahap, W. (2019). Pengaruh Faktor Risiko Hormonal pada Pasien Kanker Payudara di RSUP.Dr.M.Djamil Padang. In *Jurnal Kesehatan Andalas* (Vol. 8, Issue 3). <http://jurnal.flk.unand.ac.id>

Irawati, & Sardjan, M. (2022). Pola Persepsi Obat Kemoterapi Kanker Payudara di Rumah Sakit Lavalette Kota Malang. *PHARMADEMICA: Jurnal Kefarmasian Dan Gizi*, 1(2), 80–85. <https://doi.org/10.54445/pharmademica.v1i2.12>

Ismail, M., Khan, S., Khan, F., Noor, S., Sajid, H., Yar, S., & Rasheed, I. (2020). Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. *BMC Cancer*, 20(1). <https://doi.org/10.1186/s12885-020-06855-9>

Jamali, J., Dayo, A., Memon, N., Mughal, U.-R., Khatri, M. A., Muhammad, S., Qureshi, Y., & Khan, T. (2021). Assessment of Patient's Response about Adverse Drug Reactions Receiving AC (Adriamycin, Cyclophosphamide) Therapy: A Survey Research. *Journal of Pharmaceutical Research International*, 8–13. <https://doi.org/10.9734/jpri/2021/v33i26a31467>

Koni, A. A., Nazzal, M. A., Suwan, B. A., Sobuh, S. S., Abuhaeem, N. T., Salman, A. N., Salameh, H. T., Amer, R., & Zyoud, S. H. (2022). A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs. *BMC Cancer*, 22(1). <https://doi.org/10.1186/s12885-022-09649-3>

Kurniawati, F., Yasin, N. M., Dina, A., Atana, S., & Hakim, S. N. (2021). Kajian Adverse Drug Reactions Terkait Interaksi Obat di Bangsal Rawat Inap Rumah Sakit Akademik UGM. *JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)*, 10(4). <https://doi.org/10.22146/jmpf.60228>

Laban, A., Birand, N., Chukwunyere, U., Abdi, A., & Basgut, B. (2021). Evaluation of drug-drug interactions in cancer patients treated at a university hospital in North Cyprus using two interaction databases. *Nigerian Journal of Clinical Practice*, 24(7), 1067–1071. https://doi.org/10.4103/njcp.njcp_266_20

Lexicom. (2023). *Drug Referential Solution: https://www.wolterskluwer.com/en/solutions/uptodate/enterprise/lexidrug*.

Mantang, A., Useng, Y., & Pusmarani, J. (2023). Hubungan Drug Related Problems (DRP) Kategori Interaksi Obat Pada Penggunaan Obat Pasien Hipertensi di Puskesmas Lalonggasumeeto Kabupaten Konawe. *Jurnal Pharmacia Mandala Waluya*, 2(5), 286–294. <https://doi.org/10.54883/jpmw.v2i5.60>

Nayak, J., Sahoo, S. K., & Kumar, R. (2021). Study of Anticancer Drugs Interaction with Hemoglobin by Electrochemical Methods and Molecular Docking: Implications towards Anticancer Treatment. *ChemistrySelect*, 6(17), 4098–4106. <https://doi.org/10.1002/slct.202100424>

Novita, N. F., & Destiani, D. P. (2019). Interaksi Obat Terhadap Perpanjangan Interval QT. *Farmaka*, 18(1), 110–118.

Pereira-Oliveira, M., Reis-Mendes, A., Carvalho, F., Remião, F., Bastos, M. de L., & Costa, V. M. (2019). Doxorubicin is key for the cardiotoxicity of FAC (5-fluorouracil + adriamycin +

cyclophosphamide) combination in differentiated H9c2 cells. *Biomolecules*, 9(1). <https://doi.org/10.3390/biom9010021>

Permana, K. A. W., Agung Yudistira Permana, M., Nisa, S., Kedokteran, F., Lampung, U., Ba, R., & Encik Maryam, R. (2019). Asosiasi Triple Negative Breast Cancer (TNBC) Dengan Mutasi BRCA-1 Dan Etnisitas. *Medula*, 9(3), 398.

Rabba, A. K., Abu Hussein, A. M., Bayan K, Sbeih, A., & Nasser, S. I. (2020). Assessing Drug-Drug Interaction Potential among Patients Admitted to Surgery Departments in Three Palestinian Hospitals. *BioMed Research International*, 1–6.

Ramasubbu, S. K., Mahato, S. K., Agnihotri, A., Pasricha, R. K., Nath, U. K., & Das, B. (2021). Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital. *Cancer Treatment and Research Communications*, 26. <https://doi.org/10.1016/j.ctarc.2020.100277>

Ramdani, R., Skarayadi, O., Indrawati, W., Hermanto, F., Wahyuni, E., Jenderal Achmad Yani, U., Farmasi, I., & Sakit Bhayangkara Sartika Asih, R. (2022). Potensi Interaksi Obat Antihipertensi Pada Pasien Geriatri Rawat Inap Di Salah Satu Rumah Sakit Kota Bandung. In *Potensi Interaksi Obat Antihipertensi.....Pharmacoscript* (Vol. 5, Issue 1).

Riechelmann, R. P., & Krzyzanowska, M. K. (2019). Drug interactions and oncological outcomes: A hidden adversary. In *ecancermedicalscience* (Issue 13). *ecancer* Global Foundation. <https://doi.org/10.3332/ECANCER.2019.ED88>

Rizo, L. M., Sánchez Gómez-Serranillos, M., Cantero, M. D., Carlos, L., Lisón, F., Peinado, I. I., Pilar, M., & Cuadrado, G.-S. (2020). Drug-Drug Interaction of Oral Antineoplastic Agents in the Cancer Patient. *Journal of Clinical Oncology*, 2(1), 1–7.

Rusdi, N. K., Sari, E. N., & Wulandari, N. (2023). Ketepatan Obat, Dosis, dan Potensi Interaksi Obat pada Pasien Kanker Paru di Rumah Sakit X Jawa Barat Periode 2019-2021. *Jurnal Sains Dan Kesehatan*, 5(3), 313–323. <https://doi.org/10.25026/jsk.v5i3.1754>

Sari, D. P., & Gumayesty, Y. (2016). Faktor-Faktor Yang Berhubungan Dengan Kejadian Kanker Payudara Di Poliklinik Onkologi Rsud Arifin Achmad Provinsi Riau. *Jurnal Ilmu Kesehatan Masyarakat, STIKES Al-Insyirah Pekanbaru*, 05(02), 84–92.

Shetty, V., Chowta, M. N., Chowta K, N., Shenoy, A., Kamath, A., & Kamath, P. (2018). Evaluation of Potential Drug-Drug Interactions with Medications Prescribed to Geriatric Patients in a Tertiary Care Hospital. *Journal of Aging Research*, 2018. <https://doi.org/10.1155/2018/5728957>

Shinta R, N., & Surarso, B. (2016). Terapi Mual dan Muntah Pasca Kemoterapi. *Jurnal THT-KL*, 9(2), 74–83.

Sun, D., Li, H., Cao, M., He, S., Lei, L., Peng, J., & Chen, W. (2020). Cancer burden in China: trends, risk factors and prevention. In *Cancer Biology and Medicine* (Vol. 17, Issue 4, pp. 879–895). *Cancer Biology and Medicine*. <https://doi.org/10.20892/j.issn.2095-3941.2020.0387>

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>

Umar, R. M. (2018). Drug-drug interactions between antiemetics used in cancer patients. *Journal of Oncological Sciences*, 4(3), 142–146. <https://doi.org/10.1016/j.jons.2018.07.003>

Wardana, N., & Ernawati, R. (2019). Hubungan Usia dan Aktivitas Fisik dengan Jenis Kanker di Ruang Kemoterapi RSUD Abdul Wahab Sjahranie Samarinda. *Borneo Student Research*, 159–165.

Williamson, S., & Polwart, C. (2016). Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines. 1–16.

Wu, R., Zhang, Z., Wang, B., Chen, G., Zhang, Y., Deng, H., Tang, Z., Mao, J., & Wang, L. (2020). Combination chemotherapy of lung cancer – co-delivery of docetaxel prodrug and cisplatin

using aptamer-decorated lipid–polymer hybrid nanoparticles. *Drug Design, Development and Therapy*, 14, 2249–2261. <https://doi.org/10.2147/DDDT.S246574>

Yeoh, T. T., Tay, X. Y., Si, P., & Chew, L. (2015). Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy. *Journal of Geriatric Oncology*, 6(4), 280–287. <https://doi.org/10.1016/j.jgo.2015.05.001>

Yu, K. Da, Ye, F. G., He, M., Fan, L., Ma, D., Mo, M., Wu, J., Liu, G. Y., Di, G. H., Zeng, X. H., He, P. Q., Wu, K. J., Hou, Y. F., Wang, J., Wang, C., Zhuang, Z. G., Song, C. G., Lin, X. Y., Toss, A., ... Shao, Z. M. (2020). Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncology*, 6(9), 1390–1396. <https://doi.org/10.1001/jamaoncol.2020.2965>

Yuliawati, Dhigna, Sardiana, E., & Savira, R. D. (2021). Analisis Potensi Interaksi Obat Pasien Geriatri di Bangsal Penyakit Dalam Salah Satu Rumah Sakit di Jambi Analysis of Drug Interaction Potential among Geriatric in the Internal Medicine Inpatient Ward at One of Hospital in Jambi. *Indonesian Journal of Pharma Science*, 1(1), 21–27.